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Introduction
Tumor necrosis factor (TNF) has been implicated in the
development and pathogenicity of infectious diseases
and autoimmune disorders, such as septic shock, arthri-
tis, and hypotension [1–4]. It plays a pivotal role in the
inflammatory cascade and, together with IL-1 and IL-6,
has been shown to mediate the acute-phase response
[5,6]. Confirmation of its significance in disease comes
from the success of clinical trials using anti-TNF therapy
to treat rheumatoid arthritis and Crohn’s disease
[7–10].
Bacterial lipopolysaccharide (LPS), or endotoxin, is found
only in Gram-negative bacterial cell walls; it can on its own
induce the acute inflammatory response and the clinical
characteristics associated with sepsis. After administra-
tion of LPS, TNF and other inflammatory mediators are
released [11,12]. Infusion of TNF initiates an inflammatory
process leading to a phenotype that is indistinguishable
from bacterial sepsis [13,14].
Recent work on tristetraprolin (TTP) has provided a new
perspective on the regulation of TNF biosynthesis. TTP
APC = allophycocyanin; ARE = AU-rich element; CM = complete media; ELISA = enzyme-linked immunosorbent assay; FACS = fluorescence-
activated cell sorting; FITC = fluorescein isothiocyanate; IL = interleukin; KLH = keyhole limpet hemocyanin; LPS = lipopolysaccharide; MESF =
milliequivalents of soluble fluorescein; RPMI = Roswell Park Memorial Institute [medium]; RT-PCR = reverse transcriptase polymerase chain
reaction; TNF = tumor necrosis factor; TNFR = TNF receptor; TTP = tristetraprolin; WBC = white blood cell.
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Abstract
Tumor necrosis factor (TNF) has been implicated in the
development and pathogenicity of infectious diseases and
autoimmune disorders, such as septic shock and arthritis. The
zinc-finger protein tristetraprolin (TTP) has been identified as a
major regulator of TNF biosynthesis. To define its intracellular
location and examine its regulation of TNF, a quantitive
intracellular staining assay specific for TTP was developed. We
establish for the first time that in peripheral blood leukocytes,
expression of endogenous TTP is confined to the cytoplasm.
Baseline expression of TTP was higher in monocytes than in
lymphocytes or neutrophils. After in vitro incubation with
lipopolysaccharide (LPS), leukocyte TTP levels increased
rapidly, peaking after approximately 2 hours. Monocytes showed
the greatest response to LPS stimulation and lymphocytes the
least. TTP levels were also studied in leukocytes isolated from
healthy volunteers infused with a bolus dose of LPS. TTP
expression and initial upregulation in response to LPS infusion
were consistent with the in vitro data. Neutrophil TTP levels
responded first, reaching an initial peak within 1 hour, monocyte
levels peaked next at 2 hours, followed by lymphocytes at
4 hours. This response paralleled plasma TNF levels, which
peaked 2 hours after infusion and were no longer detectable
after 12 hours. A second rise in intracellular TTP levels, which
did not parallel plasma TNF levels, was observed in all leukocyte
populations, starting 12 hours after infusion. These data
establish the cytoplasmic location of TTP, supporting a major
role for this protein in regulating TNF production, and suggest
that TTP levels are not regulated solely by TNF.
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(also referred to as NuP475, TIS11, or GOS24) is a
member of the family of zinc-finger proteins that was origi-
nally identified through genetic screens designed to iden-
tify immediate early response genes [15–18]. TTP was
shown to be an unusually proline-rich protein with a pre-
dicted molecular weight of 33.6kDa. Its name derives
from the presence of three PPPPG amino acid repeats
that are conserved across species. There are two Cys-
Cys-Cys-His (CCCH) zinc fingers, which are responsible
for RNA binding [17,19]. There are no studies of the sub-
cellular localization or the regulation of expression of
native TTP in freshly isolated cells or tissue. Transfection
studies using nonhematopoietic cell lines or prolonged
cell culture have suggested that TTP is found in both cyto-
plasm and the nucleus [20–24].
A deficiency of TTP is associated with a profound proin-
flammatory phenotype. TTP-deficient mice exhibit
cachexia, with dermatitis, medullary and extramedullary
hyperplasia, erosive polyarthritis, and autoimmunity with
autoantibodies [25]. This phenotype is similar to that
observed in mice that overexpress TNF [26]. In agreement
with these data, TTP-deficient mice were shown to over-
produce TNF, and weekly injections of a neutralizing anti-
body to TNF eliminated the predominant features of this
phenotype. In addition, mice with the double deletion of
TTP and TNF receptor (TNFR)-1 do not manifest the
aggressive inflammation observed in TTP-deficient mice.
In contrast, mice deficient in TTP and TNFR-2 show a
more severe phenotype, suggesting a protective role for
this receptor [27].
The increase in TNF biosynthesis in TTP-deficient mice is
associated with increased mRNA stability [23]. TTP
binds to the AU-rich element (ARE) in the 3′ untranslated
region of TNF mRNA, which regulates TNF mRNA
turnover in vivo [28]. The interaction between TTP/TNF
and the ARE promotes the turnover of TNF mRNA. TTP
also regulates the stability of GM-CSF (granulocyte/
macrophage-colony-stimulating factor) mRNA through
the ARE, and therefore TTP deficiency is associated with
increased production of GM-CSF and with myeloid
hyperplasia. This is not a TNF-dependent effect, since
the phenotype is not affected by the removal of either
TNFR-1 or -2 or by the addition of TNF antibody [27].
Recent studies have suggested a potential interaction
between TTP and both IL-3 and IL-8 via the ARE in their
mRNA [29,30].
All studies of TTP expression to date have relied on trans-
fected cells and cell lines; there have been no studies on
the localization of expression of human TTP, or on its reg-
ulation in vivo or in freshly isolated normal cells. To
examine the kinetic relation between TNF production and
TTP expression in models of septic shock, we developed
an intracellular flow cytometric assay. By this method,
expression of TTP was determined in peripheral blood
leukocytes after the response to in vitro stimulation with
LPS. TTP was initially upregulated in all the cells in
response to LPS, as shown by flow cytometry and confo-
cal microscopy. The contribution of TNF to this LPS-
induced upregulation was confirmed using a humanized
monoclonal antibody to TNF. The kinetics of TTP produc-
tion was also examined in four individuals infused with
LPS. After in vivo exposure to LPS, the initial rise in TTP
expression correlated with the plasma TNF level. We also
observed secondary increases in some individuals,
without parallel increments in TNF. These observations
suggest that there are multiple factors involved in the reg-
ulation of TTP.
Materials and methods
Generation of antihuman TTP polyclonal antibody
A peptide corresponding to the C terminus (amino acids
302–328) of human TTP was synthesized, purified by
HPLC, and coupled to KLH (keyhole limpet hemocyanin;
Macromolecular Resources, Fort Collins, CO, USA). Anti-
human TTP polyclonal antibody was generated by immu-
nization of New Zealand white rabbits with the
KLH-coupled TTP C-terminal peptide (GeneMed, San
Francisco, CA, USA). The rabbit antiserum obtained was
affinity-purified by passage over a Sulfolink column
(Pierce, Rockford, IL, USA) to which disulfide linkage of
the peptide had been used to immobilize the peptide.
Specificity in Western blotting and flow cytometry was
evaluated by detection of exogenous TTP in transfected
293 cells and by blocking this activity with peptide [24].
Generation of TTP vector constructs
Human TTP cDNA was generated by RT-PCR from THP-1
RNA and cloned into the pcDNA 3.1His-C vector (Invitro-
gen, Carlsbad, CA, USA), which encodes a histidine and
epitope (EXPRESS-TAG) at the N-terminus of the protein.
Orientation of the cloned DNA and the integrity of the
DNA sequences were confirmed by sequencing with the
ABI Prism Dye Terminator Cycle Sequencing kit
(PerkinElmer, Wellesley, MA, USA), and searched against
the published sequence (TTP accession no. M63625) on
the NCBI Database using the BLAST search program.
Transient transfection
Human embryonic kidney 293 cells (ATCC, Manassas,
VA, USA) were plated at a density of 160,000 cells per
cm2 in 6-well plates (Costar, Cambridge, MA, USA). TTP
(1µg) or the TTP parental vector pcDNA3.1 His-C
(control) was mixed with 50µl of serum-free RPMI
(Roswell Park Memorial Institute) medium. The DNA was
mixed with 2µl of Lipofectamine 2000 reagent (Life Tech-
nologies, Rockville, MD, USA) in a total volume of 50µl of
serum-free RPMI per cm2 of cells, incubated for 3 hours,
and followed by the addition of an equal volume of media
containing 20% fetal calf serum.Arthritis Research & Therapy    Vol 5 No 4 Fairhurst et al.
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Cell preparation
THP-1 (generously provided by Dr P Guyre, Dartmouth
Medical School), Jurkat (ATCC), and 293 cell lines were
cultured in RPMI complete medium (CM), consisting of
RPMI 1640 with 10% heat-inactivated fetal bovine serum,
0.1ml of sodium pyruvate, 2.0mmol/l of L-glutamine,
25mmol/l of 1M HEPES (N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid), 0.1mmol/l of nonessential amino
acids, 0.25µg/ml of amphotericin, 50µg/ml gentamicin (all
from BioWhittaker, Walkersville, MD, USA) and 5×10-5M
2-mercaptoethanol (Sigma, St Louis, MO, USA). Trans-
fected and nontransfected 293 cells were harvested using
trypsin (Life Technologies), washed twice with CM, resus-
pended to a concentration of 5×106cells/ml, and fixed
with 4% methanol-free formaldehyde (Polysciences Inc,
Warrington, PA, USA). THP-1 cells were incubated with
and without LPS, 0.1µg/ml (Escherichia coli 055:B5,
Sigma), or with and without TNF (100U/ml). In addition,
infliximab (Remicade®), 100µg/ml (Centocor Inc, Malvern,
Pennsylvania, USA), was also incubated with and without
LPS or TNF to determine how much effect TNF has on
TTP induction. Preliminary studies on TNF-induced IκBα
phosphorylation determined the optimum concentration
for inhibition with infliximab. After incubation, the cells
were washed in staining buffer and fixed with 1%
formaldehyde.
Leukocytes from healthy donors were isolated by dextran
sedimentation from heparinized peripheral blood. In some
experiments, blood was combined 1:1 with RPMI CM and
incubated with or without 0.1µg/ml LPS. At the indicated
times, blood was mixed 1:1 with 2% dextran (150kDa;
Polysciences) in prewarmed RPMI and left at 37°C for
20 min to sediment the red blood cells preferentially. The
white-cell supernatant was then aspirated, centrifuged,
and mixed 1:5 with CM. After centrifugation, the cell pellet
was resuspended with staining buffer (prechilled to 4°C)
consisting of phosphate-buffered saline solution with
0.2% BSA and 1µg/ml sodium azide. The white cells
were then counted using Turks solution (0.01% crystal
violet and 3% acetic acid in distilled water), washed as
before, and resuspended to a concentration of
5×10 6cells/ml with staining buffer.
Immunofluorescence staining
To detect extracellular antigens, cells were pipetted into a
96-well polypropylene plate (Costar), and the plate was
centrifuged at 400g for 5 min. The cells and reagents
were kept at 4°C for the remainder of the experiment. The
supernatant was aspirated, and the cells were resus-
pended in 6% human IgG (Sigma) in staining buffer to
block nonspecific binding. Allophycocyanin (APC)-conju-
gated CD14 (Becton, Dickinson and Co, San Jose, CA,
USA) was added, and the cells were incubated for a
further 20 min in the dark. The cells were then washed
once in staining buffer and residual red blood cells lysed
with FACSTM Lysing solution (Becton Dickinson). After
5 min the cells were washed twice with staining buffer and
fixed overnight in 1% formaldehyde.
To detect intracellular TTP, fixed cells were washed twice
in permeabilization buffer (consisting of staining buffer
with the addition of 1µg/ml saponin), centrifuged as
before, and incubated for 30 min at 4°C in blocking buffer,
consisting of 3% IgG with 3% nonfat powdered milk for
leukocytes in permeabilization buffer. The plate was cen-
trifuged, the supernatant was aspirated, and 3.8µg per
5×10 5cells of anti-TTP rabbit polyclonal or control anti-
body (DAKO A/S, Glostrup, Denmark) was added for 45
min more. After incubation, the cells were washed in per-
meabilization buffer and resuspended in FITC-conjugated
F(ab′)2 (antigen-binding fragment) donkey antirabbit IgG
(25µg/ml, Jackson ImmunoResearch, West Grove, PA,
USA) for 45 min at 4°C. Cells were washed with perme-
abilization buffer and then with staining buffer. They were
resuspended with 1% formaldehyde and stored in the
dark at 4°C until analysis. For the infliximab inhibition
experiments, a goat polyclonal antibody to TTP was used
(Santa Cruz Biotechnology Inc, Santa Cruz, CA) with a
secondary swine antigoat FITC-conjugated IgG antibody
(Sigma). Preliminary experiments showed that the affinity
of this antibody for TTP was equivalent to that of the rabbit
polyclonal antibody.
In the LPS infusion study, TruCount® calibration beads
(Becton Dickinson) were quantitatively added to the
stained cells. Enumeration of individual leukocyte counts
was then completed using Cell Quest® software.
FACS analysis and confocal microscopy
Analysis by flow cytometry was completed using a FAC-
SCalibur (Becton Dickinson). Contaminants, such as red
cells and cell debris, were removed by forward and side
scatter gating; in addition, CD14 versus side scatter was
used to create gates to differentiate lymphocytes, mono-
cytes, and neutrophils. Fluorescein fluorescence was
detected through the FL-1 channel, APC fluorescence
was assessed using the FL-4 channel, and data were
acquired and analyzed using the CellQuest® application
on a Power Macintosh G3 computer. For each sample, at
least 2000 monocytes were collected and the mean fluo-
rescence intensity was evaluated. Calibration was done
using Rainbow Microspheres (Spherotech Inc, Libertyville,
IL, USA), with final values expressed as the milliequiva-
lents of soluble fluorescein (MESF) [31].
293 cells were sorted for the brightest FITC fluorescence
using a FACStar Plus flow cytometer (Becton Dickinson).
Cells were collected into tubes containing 100µl fetal calf
serum, centrifuged, and resuspended in 1% formalde-
hyde. The cells were stored overnight at 4°C in the dark.
TTP/FITC-stained white blood cells or THP-1 cells werecentrifuged and resuspended in formaldehyde as for 293
cells. Nuclear staining was done using propidium iodide
0.01mg/ml (Sigma). For confocal microscopy, cells were
pipetted from the base of the settled cell suspension and
placed onto a glass slide with Prolong® Antifade (Molecu-
lar Probes, Eugene, OR, USA) to inhibit quenching. The
cells were then covered with a cover slip protected with
clear nail polish.
Microscopy for FITC-conjugated TTP analysis was com-
pleted using a BioRad MRC1024 laser scanning confo-
cal microscope (BioRad, Hercules, CA, USA). Cells
were scanned for fluorescence using the 488-nm line
from a 15-mW Kr/Ar laser and two photodetectors
(522/32-nm dichroic for FITC fluorescence and 585-nm
longpass for propidium iodide fluorescence). A 63×
Plan-APO 1.4 NA objective (Carl Zeiss Inc, Thornwood,
NY, USA) was used in conjunction with an iris setting of
2.5, which allowed for detection of optical sections of
the fluorescence image that were approximately 0.5µm
thick. Representative images were selected from the
slices though the center of the cells after sectioning
through the entire cell.
LPS infusion
Consenting volunteers were given an intravenous bolus of
endotoxin in accordance with a protocol approved by the
Institutional and Scientific Review Boards of the Dart-
mouth-Hitchcock Medical Center and Norris Cotton
Cancer Center, Lebanon, NH, USA. One month before
admission and again just before admission, the volunteers’
physical wellbeing and health were assessed, and current
medications were noted. The infusion was conducted in
the intensive care unit at Dartmouth-Hitchcock Medical
Center with continuous supervision for the first 12 hours.
Blood pressure, heart rate, and body temperature were
evaluated throughout this period.
Clinical Center reference endotoxin (CCRE), lot O:133,
derived from E. coli (United States Pharmacopeia Conven-
tion Inc, Rockville, MD, USA [32]), was injected intra-
venously at a dose of 4ng/kg. Three consecutive baseline
blood samples were taken, at 15, 10, and 5 min before
infusion, and samples were taken at 0.45, 1, 2, 4, 8, 12,
24, 48, and 72 hours after infusion, from a peripheral,
indwelling, venous catheter directly into a heparinized
syringe (Becton Dickinson). Blood was sedimented in
dextran, extracellularly stained for CD14, and fixed with
1% formaldehyde. The cells were stored overnight at 4°C
and then stained for intracellular TTP. A human TNF ELISA
kit (R&D Systems, Minneapolis, MN, USA) was used to
determine the concentration of TNF in plasma from periph-
eral blood, in accordance with the manufacturer’s instruc-
tions. The TNF-α standard was made up as directed to
read a maximum concentration of 1000pg/ml and a
minimum of 15.6pg/ml.
Statistical analysis
Analysis was by one-way analysis of variance (ANOVA)
with post hoc Bonferroni adjustment (all-means compari-
son) test, using the Graphpad® Prism version 3.00 for
Windows (Graphpad Software, San Diego, CA, USA).
Results
Optimization and specificity of the TTP polyclonal
antibody
To determine the optimal working concentration of the
TTP antibody, 293 cells transfected with TTP were fixed,
permeabilized, and stained at various concentrations of
antibody or IgG control. There was a concentration-
dependent increase in fluorescence (Fig.1a), which was
standardized using fluorescent microspheres in order to
compare different experiments and cell types [31]. The
optimum concentration of antibody was determined to be
3.8µg per 5×105cells, where the intensity curve began
to flatten. At higher concentrations, the MESF value for the
control sera increased concordantly, indicating nonspe-
cific binding. Specificity of the TTP antibody was deter-
mined by blocking with the identical peptide sequence
used to generate the polyclonal antibody. In the presence
of blocking TTP peptide, at concentrations either 10 or 50
times the amount of TTP antibody used, the detection of
the TTP protein within the transfected cells was nearly
eliminated (Fig.1b).
Confocal sectioning of transfected 293 cells showed that
the presence of TTP protein was primarily in the cytoplas-
mic fraction (Fig.1c). Z sections taken every 0.5µm
through the cell showed little, if any, TTP within the
nucleus. In nontransfected 293 cells, a small amount of
TTP was detected by flow cytometry and confirmed by
confocal microscopy. Transfected 293 cells expressed
nine times as much TTP as the untransfected cells at the
optimal working concentration of antibody. Preincubation
of the nontransfected 293 cells with TTP peptide blocked
the activity, confirming its identity. These results confirmed
our previously published data in which Western blot analy-
sis showed that TTP was localized in the cytoplasmic
extract of 293 cells [24].
Induction of TTP in the THP-1 cell line
Since TNF biosynthesis in macrophages is rapidly trig-
gered by treatment with LPS, the effects of this endotoxin
on TTP expression were examined. THP-1 cells, a human
myelomonocytic cell line, were incubated with and without
LPS (0.1µg/ml) for up to 24 hours. At representative time
points, a sample was removed and stained with either anti-
TTP or the IgG control, as described in Materials and
methods. The addition of LPS rapidly increased the
expression of TTP by THP-1 cells (Fig.2a). Increases in
TTP were detectable 1 hour after stimulation and were still
evident in the cytosol 4 hours after LPS treatment. Analy-
sis of the cells by confocal microscopy (Fig.2b) confirmed
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expressed intracellularly, relatively homogeneously but
confined to the cytoplasm. These data show that LPS
stimulation rapidly increases human TTP protein expres-
sion in the cytoplasm. The kinetics of induction by LPS
parallels that seen with TTP mRNA in bone-marrow-
derived murine macrophages [23].
In vitro TTP induction with LPS in peripheral blood
leukocytes
Modulation of TTP expression by LPS was subsequently
examined in normal peripheral leukocytes. Whole blood
from eight healthy volunteers was incubated at 37°C alone
or with LPS (0.1µg/ml) for up to 24 hours. At periodic
time points, a sample was taken and leukocytes were puri-
fied by dextran sedimentation, fixed, permeabilized, and
then stained with either anti-TTP or control antibody. In
leukocytes, constitutive expression of TTP ranged from
approximately 9×103 to 35×103 MESF. Monocytes con-
stitutively expressed over three times as much TTP as
either lymphocytes or neutrophils (Table 1). Stimulation
with LPS in vitro produced an increase in TTP expression
in all leukocyte subpopulations. This was maximal 2 hours
after stimulation. TTP levels increased to a higher maximal
level in monocytes than in other leukocytes (+8.5×103
MESF; Fig. 3a). Two-color flow cytometry indicated that
CD4+ and CD8+ T lymphocytes expressed equivalent
amounts of TTP (data not shown). The kinetics of TTP
induction with LPS was consistent and monophasic in all
leukocytes (Fig.3i). The change in TTP expression was
greatest in neutrophils and least in lymphocytes. Since
lymphocytes lack Toll-like receptor 4 and express little or
no CD14 [33], we conclude that the induction of TTP in
these cells was occurring indirectly, presumably through
stimulation with TNF, although other cytokines, including
IL-1, IL-6, and IL-8, could contribute to this response.
Arthritis Research & Therapy    Vol 5 No 4 Fairhurst et al.
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Figure 1
Saturation curve and specificity of the tristetraprolin (TTP) polyclonal antibody. Results are shown as milliequivalents of soluble fluorescein±SE and
are representative of two separate experiments. (a) Nontransfected and transfected 293 cells were stained with increasing concentrations of the
rabbit-derived anti-TTP antibody, or a rabbit IgG control, and then with secondary FITC-conjugated donkey antirabbit IgG. (b) Specificity was
demonstrated by introducing the TTP peptide at 10 and 50 times the concentration of the antibody used. All bars derive from the transfected
phenotype. (c) Confocal microscopy of cells stained as described for TTP and nuclear staining with propidium iodide. Ab=antibodies;
MESF=milliequivalents of soluble fluorescein; SE=standard error of the mean.
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)LPS-induced TTP upregulation was confirmed in all cell
types by confocal microscopy. Analysis confirmed an
increase in TTP in neutrophils 2 hours after stimulation
(Fig.3). Similar data were obtained for lymphocytes and
monocytes (data not shown). Distribution in resting levels
and after stimulation with LPS was primarily cytosolic,
which is in accord with our data for 293 and THP-1 cells.
Correlation of in vivo TTP production with TNF after LPS
bolus
To study the kinetics of TTP induction in vivo, we infused
4ng/kg of clinical-grade endotoxin at time 0 in four volun-
teers. Blood was drawn before the infusion and at speci-
fied intervals afterwards, and aliquots were analyzed for
leukocyte cell counts, TTP expression, and plasma TNF
levels.
The cell counts of all the leukocyte subpopulations in all
the volunteers fell rapidly, as seen 1 hour after infusion in
all volunteers (Fig.4a–c), in concordance with published
data [34–36]. Beyond the 1-hour time point, the neu-
trophil cell count increased, reaching a peak at 12 hours. It
then decreased to baseline values at 24 hours (Fig.4a).
Lymphocyte and monocyte data showed similar initial
kinetics. The lymphocyte and monocyte curves were
biphasic, peaking at 4 hours, dropping to baseline at
12 hours, and beginning a second increase at 48 hours.
Plasma TNF levels were analyzed throughout the study.
The circulating TNF level increased to a peak at 2 hours
after infusion (Fig. 4d). After 12 hours, there was no
detectable TNF in any of the four volunteers. This
monophasic peak was consistent with findings in other
studies [37].
Analysis of TTP expression in leukocyte populations
before and after LPS infusion revealed a biphasic induc-
tion, with an initial peak occurring within 4 hours and a
second after 12 hours (Fig.5a–c). Baseline and maximum
TTP expression in each cell type for each volunteer is pre-
sented in Table 2. The expression and initial upregulation
of TTP in response to LPS in all leukocyte populations
was consistent with the data found in vitro. Neutrophils
responded rapidly to LPS infusion, reaching an initial peak
within an hour of infusion, although the average increase in
the four volunteers appears to be moderate (50%). Analy-
sis of monocytic TTP showed an increase in expression,
peaking at 2 hours (Fig.5b). Lymphocyte TTP expression
peaked at 4 hours, which was later than the initial peak
response of neutrophils and monocytes (Fig.5c). A
second, more dramatic, rise, which did not parallel
changes in plasma TNF levels (Fig.5d), was observed
12 hours after infusion in all leukocyte populations.
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Table 1
Constitutive expression of tristetraprolin in peripheral blood
leukocytes
MESF (in thousands)
Cell type Baseline expressiona Range
Lymphocyte 9.5 (1.2) 4.45–14.17
Monocyte 35.4 (3.3)* 13.90–44.32
Neutrophil 13.8 (3.3) 9.14–18.28
Intracellular TTP levels were detected using the TTP antibody in
conjunction with a fluorescein-labelled antirabbit Ig. Background levels
were subtracted from these results and CD14-staining plus forward
and side scatter gating permitted specific analysis of TTP expression in
the leukocyte populations. Monocytes have a significantly higher
constitutive TTP expression than other leukocytes. aMean (SE); n=8.
*P<0.001. MESF=milliequivalents of soluble fluorescein.
Figure 2
Lipopolysaccharide (LPS) induction of tristetraprolin (TTP) in resting
THP-1 cells. Cells were incubated with and without LPS and then at
specific times were permeabilized and stained with TTP antibody or a
rabbit IgG control. (a) Induction was rapid, reaching a maximum at 1
hour. Results are expressed as the percentage change over baseline in
MESF ± SE (n = 3). Significant increases are shown with respect to
time 0 (*P < 0.05, **P < 0.01). (b) Confocal microscopy reveals the
basal expression of TTP at time 0, and the upregulation at 2 hours after
LPS treatment. The left panel shows the expression before LPS
incubation, the right, after LPS stimulation. Nuclear staining was
completed with propidium iodide. MESF = milliequivalents of soluble
fluorescein; SE = standard error.
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The human in vivo studies described here show increases
in circulating plasma TNF that preceded TTP induction in
all the leukocyte types investigated. This observation is
consistent with the hypothesis that LPS mediates induc-
tion of TTP through the production of TNF. However, this
hypothesis does not explain the second rise in TTP we
observed in vivo, which was not associated with TNF. To
examine this phenomena in more detail, THP-1 cells were
cultured with LPS or TNF in the presence of blocking TNF
antibody. The antibody sequesters TNF in the supernatant,
preventing its interaction with TNF receptors. LPS
induced greater TTP expression than TNF (Fig.6a,b).
When THP-1 cells were stimulated with LPS in the pres-
ence of the blocking TNF antibody, the TTP response was
reduced but not eliminated (Fig.6a). In fact, the initial
induction of TTP detectable during the first hour was unaf-
fected, suggesting that TNF was not solely responsible for
the LPS-induced rise. In contrast, TNF induction of TTP by
THP-1 cells was completely blocked in the presence of
the blocking TNF antibody (Fig.6b).
Discussion
This study is the first to evaluate the expression and regu-
lation of endogenous human TTP in myeloid and lymphoid
cells. It is the first to examine the subcellular localization
Arthritis Research & Therapy    Vol 5 No 4 Fairhurst et al.
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Figure 3
Changes in tristetraprolin (TTP) expression by leukocytes after lipopolysaccharide (LPS) stimulation in vitro. (a) LPS induced TTP expression in all
leukocytes. Results are expressed as the LPS-induced increase in TTP specific staining over baseline expression. Significant increases are shown
with respect to time 0 (*P<0.05 monocytes or lymphocytes; #P<0.05 neutrophils; n=8). Monocyte recovery was poor at time points beyond
4 hours and these results are excluded. (b) Confocal microscopy shows the upregulation of TTP in neutrophils 2 hours after LPS stimulation.
Neutrophils before (i-iii) and after (iv-vi) LPS stimulation. (i,iv) transmitted light (differential interference contrast) image of the cell; (ii,v) TTP (FITC);
(iii,vi) composite image, nuclear material stained red with propidium iodide.
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) #of native TTP protein in freshly isolated cells, since all pre-
vious studies relied on prolonged cell culture or transfec-
tion/overexpression approaches using cell lines
[20–22,24,25]. We show that endogenous human TTP is
expressed in neutrophils, lymphocytes, and monocytes.
They are significant in their demonstration that native
human TTP is totally cytoplasmic; there was little evi-
dence of nuclear localization in these studies, an observa-
tion that is consistent with previous work with human
TTP, in which immunoblotting showed cytoplasmic local-
ization [24].
The discrepancy between our findings and findings of
nuclear localization of TTP may be due to several factors
[20–22,24,25]. First, most of those studies did not
measure endogenous TTP but usually relied on transfec-
tion of cell lines, perhaps resulting in mislocalization due to
the presence of an epitope tag or overexpression
[20–22,24,25]. Second, by definition, those cells were
largely cycling and thus were not representative of normal
hematopoietic cells. Third, mouse or rat TTP was used in
those studies [20–22,25]. Although highly conserved, it is
possible that human TTP is subtly different from rodent
TTP. We think this unlikely, as immunoprecipitation
studies of bone-marrow-derived murine macrophages
show murine TTP predominantly in the cytoplasmic frac-
tion [23]. This matter requires further analysis once
improved antibodies to murine TTP are generated.
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Table 2
Expression in vivo of tristetraprolin in volunteers
Volunteer
no. Neutrophils Lymphocytes Monocytes
1 Baseline 16.5 (1.2) 18.8 (1.0) 15.6 (1.6)
Peak 54.9 (2.0) 90.4 (8.8) 18.9 (2.4)
2 Baseline 15.6 (1.2) 9.9 (1.0) 23.2 (2.0)
Peak 17.1 (3.6) 13.1 (1.2) 40.8 (4.3)
3 Baseline 9.7 (8.2) 4.2 (0.5) 20.8 (1.3)
Peak 20.8 (1.4) 9.4 (2.3) 62.0 (29.0)
4 Baseline 13.6 (1.1) 6.0 (0.6) 16.6 (1.7)
Peak 17.5 (1.1) 19.1 (1.8) 47.2 (1.6)
Values are mean milliequivalents of soluble fluorescein (SE) (in
thousands). Human subjects were infused with a bolus dose of
lipopolysaccharide at T=0. Blood was drawn at specific times before
and after infusion, and the leukocytes were purified by dextran
sedimentation. Expression of tristetraprolin was determined by flow
cytometry.
Figure 4
White blood cell count in four volunteers at various times after infusion with lipopolysaccharide. Cell numbers for (a) neutrophils, (b) lymphocytes,
and (c) monocytes. Plasma TNF levels (d) were measured by ELISA. TNF=tumor necrosis factor.
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Figure 5
The effect of lipopolysaccharide (LPS) on leukocyte tristetraprolin (TTP) expression in vivo. Four human subjects were infused with a bolus dose of
LPS at T=0. Blood was drawn at specific times before and after infusion, the leukocytes were purified, and expression of TTP was determined. The
graphs show the percentage change in TTP expression in (a) neutrophils, (b) lymphocytes, and (c) monocytes with respect to values before
infusion, where a doubling in TTP expression is 100% (mean±SE; n=4).
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Figure 6
Contribution of tumor necrosis factor (TNF) to lipopolysaccharide (LPS) induction of tristetraprolin (TTP) in THP-1 cells. The cells were incubated
with LPS (a) or TNF (b) in the absence or presence of blocking TNF antibody (infliximab [Remicade]), and TTP levels were measured at specific
times. Results are expressed as percentage change from baseline expression (mean±SE). Experiments were performed in duplicate.
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Our studies clearly showed human TTP in lymphocytes
and neutrophils, in addition to monocytes. Early work by
Carballo and colleagues [38] showed the importance of
macrophages, not lymphocytes, in the development of the
phenotype associated with TTP deficiency. This highlights
the importance of macrophages in the production of TNF,
supported by current hypotheses on the pivotal role of this
cell type in TNF overproduction in autoimmune diseases
[39]. Thus, our findings suggest that TTP serves an
entirely different role in other leukocytes, relative to their
role in regulating cytokine production by macrophages,
and that TNF production is not simply regulated by TTP.
Despite these potential differences in the function of
human TTP based on cell type, our studies show a
common pattern of induction by LPS in monocytes, neu-
trophils, and lymphocytes. The upregulation of human TTP
occurs rapidly, within the first hour of stimulation. This is
consistent with murine data demonstrating that upregula-
tion occurs within 30 min of LPS stimulation, remaining
high for 4 hours [23]. Using confocal imaging, we found
TTP was primarily detected in the cytoplasmic fraction,
confirming our earlier immunoblotting studies [24].
LPS stimulation of peripheral blood leukocytes in vitro
revealed TTP-induction kinetics analogous to that
observed for THP-1 cells. We used a whole blood assay,
since the cytokines produced after in vitro incubation with
LPS are analogous to those produced after in vivo infu-
sion, providing an important model of sepsis [40]. Base-
line expression of TTP was higher in monocytes than in
either lymphocytes or neutrophils. Lymphocytes
responded the least to LPS stimulation, whereas mono-
cytes responded the most. Monocytes were not followed
beyond 4 hours after stimulation with LPS, because of the
low numbers of cells retrieved, probably due to upregula-
tion of adhesion molecules (ICAM-1) [41].
The induction of TTP expression by either LPS or TNF has
not been studied in an in vivo system before. In this study,
four human volunteers were infused with LPS and the sub-
sequent changes in leukocyte cell count, TTP expression
in leukocyte subpopulations, and levels of TNF were fol-
lowed over a 72-hour period. Although there was some
individual variability in the overall kinetics, basal levels and
the initial induction of TTP by LPS were within the range
observed in vitro (Tables 1 and 2). All cell types showed
an increase in TTP expression within the first hour. Inter-
estingly, TTP was induced by LPS in vivo more slowly
(after 4 hours vs 1–2 hours) and to a lesser degree in the
lymphocyte population than in neutrophils or monocytes.
The absence of LPS-signal transducers (CD14, Toll-like
receptor 4) on most lymphocytes relative to monocytes
and neutrophils may account for this altered expression
[42,43]. Since lymphocytes express TNF receptors and
TNF itself can induce TTP mRNA expression [38], these
data are consistent with the interpretation that TTP induc-
tion in lymphocytes is transduced not by LPS binding, but
by TNF produced by monocytes and/or neutrophils acting
on lymphocytes.
The initial fall in leukocyte cell count observed in vivo is in
accord with published data [34–36]. The numbers of
monocytes and neutrophils dropped within the first hour,
by approximately 98% and 76%, respectively, and of lym-
phocytes, by 80% after 4 hours. This decrease is consis-
tent with data suggesting that the reduction in leukocytes
results from a decrease in granulocytes and monocytes as
they become activated, migrating and adhering to vascular
endothelium [44]. This drop in cell numbers was followed
by an increase in all leukocyte populations, beginning at
12 hours and continuing through the 72-hour time point.
This raises the issue of whether the apparent changes in
TTP expression were due, in part, to differential rates of
margination by leukocyte subpopulations. Since the levels
of TTP induction seen in the first hour in vivo approximate
those seen in vitro, we believe that this induction reflects
the increased synthesis and expression of TTP by all
leukocyte subpopulations and is consistent with the kinet-
ics of their mRNA induction [23].
TTP and TNF are reportedly involved in a negative-feed-
back loop, in which increases in TNF concentration are
associated with induction of TTP [23]. In these studies,
LPS, which induces the release of TNF [45], produced a
rise in TTP within 4 hours of stimulation. Although the
initial rise in TTP in vivo paralleled a rapid and consider-
able increase in plasma TNF, the second, late increases in
intracellular TTP did not reflect TNF levels. This change
may have been mediated by other cytokines (IL-1β, IL-8)
whose levels have been shown to increase with kinetics
that parallel this rise in TTP [40,46,47]. Alternatively, the
late rise in cytoplasmic TTP may be due to release from
the bone marrow of leukocytes that have high levels of
TTP or an adaptive response to endotoxemia.
TNF overproduction mediates both sepsis and chronic
inflammatory disorders such as RA. Its production may be
modulated at transcriptional, post-transcriptional, and
post-translational levels [48–50]. Many of the effects
observed after LPS stimulation can be attributed to subse-
quent production of TNF. Moreover, infusion of TNF initi-
ates inflammatory processes, with a resulting phenotype
that is indistinguishable from bacterial sepsis [13,14]. We
investigated the contribution of TNF in the LPS-mediated
induction of TTP in THP-1 cells using a blocking TNF anti-
body. TNF induction of TTP expression was almost com-
pletely eliminated by incubation with the TNF inhibitor,
proving the direct effect of TNF on TTP induction. LPS,
however, induced much greater levels of TTP in THP-1
cells than TNF did. In the presence of blocking TNF anti-
body, LPS induction of TTP was initially unaffected butbegan to decline after 1 hour, suggesting that LPS itself
may mediate the initial increases in TTP and showing that
the prolonged induction of TTP is dependent on TNF.
Conclusion
We have shown through an intracellular staining assay
that human TTP expression is modulated by LPS and TNF.
LPS-induction of TTP was partly dependent on the pro-
duction of TNF. The ability of LPS to induce TTP indepen-
dently of TNF may account for the earlier response
observed in neutrophils and monocytes that have LPS-sig-
naling transduction molecules. In contrast, lymphocytes
demonstrate a delayed and lower TTP response and are
probably responding to TNF, or other cytokines, produced
by myeloid cells. In addition, a second rise in TTP expres-
sion was observed in vivo, which did not correlate with
any detectable rise in TNF concentration, implying that
there are additional factors involved in the regulation of
this intracellular protein. TNF is a predominant proinflam-
matory cytokine, particularly in sepsis and chronic inflam-
matory disorders suggesting that the role of its negative
regulator, TTP, may be of functional importance in the
development and pathogenesis of disease. Investigating
any potential abnormalities in expression or regulation may
prove to be a valuable therapeutic intervention.
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